Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Medacta Group SA    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Medacta : Expands its Partial Knee Replacement Solutions with MOTO Lateral Partial Knee System

share with twitter share with LinkedIn share with facebook
09/15/2020 | 02:05pm EDT

EQS Group-News: Medacta Group SA / Key word(s): Regulatory Approval
Medacta Expands its Partial Knee Replacement Solutions with MOTO Lateral Partial Knee System

15.09.2020 / 19:00


Media Release
Medacta Expands its Partial Knee Replacement Solutions with MOTO Lateral Partial Knee System

CASTEL SAN PIETRO, 15 September 2020 - Medacta announced today the first surgery utilizing its MOTO Lateral Partial Knee System, which has recently received CE marking and FDA clearance. The surgery was performed by J. Mandume Kerina, M.D., from Lady Lake, FL (USA) in early August.

MOTO Lateral is a compartment-specific, fixed-bearing implant that allows for the treatment of osteoarthritis localized on the lateral femoral and tibial condyles. This device is part of the MOTO Partial Knee System, which also includes MOTO Medial (launched in 2017), and MOTO PFJ, a new Patello-Femoral Joint implant that will be available at the beginning of 2021.

The MOTO System provides surgeons with a comprehensive range of options to resurface only the affected portion of the patient's knee. Potential benefits of this minimally invasive procedure include a shorter hospital stay, faster recovery and better knee function compared to a total knee arthroplasty. All MOTO System components feature an anatomic and compartment-specific design, based on Medacta's MyBody anthropometric database, which consists of more than 45,000 CT and MRI knee scans. This optimizes anatomic coverage and size range for the broadest range of patient populations.

The MOTO instrument platform allows for precise bone resections and the control of flexion-extension gap balancing at each step of the surgery in order to precisely resurface the affected medial or lateral compartment of the patient's knee. In keeping with its commitment to surgeon education, Medacta's M.O.R.E. Institute has also created a comprehensive Education Program dedicated to the MOTO Platform, with the goal of teaching surgeons the principles of the innovative surgical procedure using this system.

"I have been using the MOTO Medial UKA system since its release, with excellent results," said Dr. Kerina. "Now, with the addition of the MOTO Lateral to the system, I can cover almost all my tibiofemoral unicompartmental knee arthroplasties. Being able to provide my patients with a wider range of arthroplasty options to treat their specific pathology has allowed me to greatly expand my practice. I am very excited about what the MOTO system will become when the last puzzle piece, the MOTO PFJ, will be released early next year, allowing me to treat also the patellofemoral osteoarthritis. The system offers a comprehensive range of options aiming to intra-op flexibility and patients' well-being."

MOTO PFJ (Patello-Femoral Joint), with its anticipated availability in 2021, will allow for the treatment of patellofemoral osteoarthritis without compromising the non-affected tibiofemoral knee compartments. This implant features an onlay-anterior and inlay-distal design with a broad-anterior and narrow-distal shape, conceived to restore a painless patellar movement throughout the whole articular range of motion. The dedicated surgical technique and instrumentation guide every step of the procedure, utilizing the anterior cortex as reference and completely avoiding intramedullary canal violation or any free-hand preparation.

The introduction of these innovative implants and their cutting-edge concepts is possible through the M.O.R.E. Excellence Clinical Program, which defines the steps and milestones applicable to all Medacta products ahead of their full release. Under this program, Medacta releases new products on a restricted basis to conduct voluntary clinical programs in order to further document their safety and efficacy.

Discover more about Medacta's knee portfolio at knee.medacta.com.

Contact
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch

About Medacta
Medacta is an international company specialized in the design and production of innovative orthopaedic products and the development of accompanying surgical techniques for joint replacement, spine surgery, and sports medicine. Established in 1999 in Switzerland, Medacta's products and surgical techniques are characterized by innovation. Medacta is a pioneer in developing new offerings on the basis of minimally invasive surgical techniques, in particular its Anterior Minimally Invasive Surgery (AMIS) technique for hip replacements. Medacta has leveraged its orthopaedic expertise and comprehensive understanding of the human body to develop the sophisticated MySolutions technology, which offers surgeons highly personalized pre-operative planning and implant placement methodologies by creating advanced personalized kinematic models and 3D planning tools for use in hip, knee, shoulder and spine procedures.



End of Media Release


Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch,investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1131961

 
End of News EQS Group News Service

1131961  15.09.2020 

fncls.ssp?fn=show_t_gif&application_id=1131961&application_name=news&site_id=zonebourse
© EQS 2020

share with twitter share with LinkedIn share with facebook
All news about MEDACTA GROUP SA
10/19MEDACTA : Expands its Knee Offerings with New SensiTiN System with Low Metal Ion..
EQ
10/13MEDACTA : Launches M.U.S.T. 2.0 Instrumentation to Expand its Offerings for Spin..
EQ
09/29MEDACTA : Expands its Knee Portfolio with 3DMetal Femoral Cones for Knee Revisio..
EQ
09/15MEDACTA : Expands its Partial Knee Replacement Solutions with MOTO Lateral Parti..
EQ
09/07MEDACTA : Publication of 2020 Half Year Results
EQ
09/04MEDACTA : Announces Successful Completion of the First Australian Surgery with N..
EQ
09/02MEDACTA : Receives FDA Clearance for the Lateralized Glenosphere
EQ
07/22MEDACTA : Half-year 2020 revenue equal to Euro 135M, down 11.1% over the prior y..
EQ
07/13MEDACTA TO INTRODUCE NEXTAR(TM) : First FDA-Cleared Augmented Reality-Based Surg..
EQ
06/30MEDACTA : Announces First Hip Replacement Surgeries with New Quadra-P System
EQ
More news
Financials
Sales 2020 303 M 353 M 353 M
Net income 2020 31,2 M 36,4 M 36,4 M
Net Debt 2020 114 M 133 M 133 M
P/E ratio 2020 46,5x
Yield 2020 0,57%
Capitalization 1 437 M 1 679 M 1 677 M
EV / Sales 2020 5,12x
EV / Sales 2021 4,23x
Nbr of Employees 1 126
Free-Float 30,7%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 77,35 €
Last Close Price 72,21 €
Spread / Highest target 26,7%
Spread / Average Target 7,13%
Spread / Lowest Target -19,3%
EPS Revisions
Managers
NameTitle
Francesco Siccardi Chief Executive Officer
Alberto Siccardi Executive Chairman
Corrado Farsetta Chief Financial Officer
Maria Luisa Siccardi Tonolli Non-Executive Director
Victor Waldemar Balli Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDACTA GROUP SA6.77%1 700
ABBOTT LABORATORIES22.52%188 420
MEDTRONIC PLC-9.57%137 923
BECTON, DICKINSON AND COMPANY-13.27%68 377
HOYA CORPORATION20.86%45 978
BAXTER INTERNATIONAL INC.-6.54%39 562